Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 11/2018

01-11-2018 | Original Article

Characterization of low active ghrelin ratio in patients with advanced pancreatic cancer

Authors: Tomofumi Miura, Shuichi Mitsunaga, Masafumi Ikeda, Izumi Ohno, Hideaki Takahashi, Hidetaka Suzuki, Ai Irisawa, Takeshi Kuwata, Atsushi Ochiai

Published in: Supportive Care in Cancer | Issue 11/2018

Login to get access

Abstract

Purpose

Acyl ghrelin is an orexigenic peptide. Active ghrelin ratio, the ratio of acyl ghrelin to total ghrelin, has an important role in physiological functions and gastrointestinal symptoms. However, low active ghrelin ratio-related characteristics, gastrointestinal symptoms, and chemotherapy-induced gastrointestinal toxicity in patients with advanced pancreatic cancer have not been previously evaluated. The goal of this study was to identify low active ghrelin ratio-related factors in treatment-naïve advanced pancreatic cancer patients.

Methods

Patients with treatment-naïve advanced pancreatic cancer were eligible for inclusion in this study. Active ghrelin ratio and clinical parameters of patients were prospectively recorded. Factors correlated with low active ghrelin ratio and survival were analyzed.

Results

In total, 92 patients were analyzed. Low active ghrelin ratio-related factors were advanced age (P < 0.01), severe appetite loss (P < 0.01), and decreased cholinesterase (P < 0.01). The adverse events of grade 2 or higher anorexia tended to increase in patients with low active ghrelin ratio. However, no differences were found in survival and body composition between low and high active ghrelin ratio groups.

Conclusions

Low active ghrelin ratio was related to lack of appetite and low cholinesterase and tended to be related to anorexia grade 2 or higher in patients with treatment-naïve advanced pancreatic cancer.
Literature
1.
Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656–660CrossRef
2.
Tack J, Depoortere I, Bisschops R, Delporte C, Coulie B, Meulemans A, Janssens J, Peeters T (2006) Influence of ghrelin on interdigestive gastrointestinal motility in humans. Gut 55:327–333CrossRef
3.
Fahim MA, Kataya H, El-Kharrag R, Amer DA, al-Ramadi B, Karam SM (2011) Ghrelin attenuates gastrointestinal epithelial damage induced by doxorubicin World Journal of Gastroenterology: WJG 17: 3836CrossRef
4.
Broglio F, Prodam F, Riganti F, Gottero C, Destefanis S, Granata R, Muccioli G, Abribat T, van der Lely AJ, Ghigo E (2008) The continuous infusion of acylated ghrelin enhances growth hormone secretion and worsens glucose metabolism in humans. J Endocrinol Investig 31:788–794CrossRef
5.
Ozawa T, Tokunaga J, Arakawa M, Ishikawa A, Takeuchi R, Mezaki N, Miura T, Sakai N, Hokari M, Takeshima A (2013) Abnormal ghrelin secretion contributes to gastrointestinal symptoms in multiple system atrophy patients. J Neurol 260:2073–2077CrossRef
6.
Garcia JM, Garcia-Touza M, Hijazi RA, Taffet G, Epner D, Mann D, Smith RG, Cunningham GR, Marcelli M (2005) Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J Clin Endocrinol Metab 90:2920–2926CrossRef
7.
Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE (2011) Definition and classification of cancer cachexia: an international consensus. The Lancet Oncol 12:489–495CrossRef
8.
Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer The New England journal of medicine 364: 1817–1825CrossRef
9.
Okusaka T, Ikeda M, Fukutomi A, Ioka T, Furuse J, Ohkawa S, Isayama H, Boku N (2014) Phase II study of FOLFIRINOX for chemotherapy-naive Japanese patients with metastatic pancreatic cancer Cancer science 105: 1321–1326
10.
Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691–1703CrossRef
11.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines. Antiemesis. Ver. 2. 2017
12.
Peterson DE, Bensadoun RJ, Roila F (2011) Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 22 Suppl 6: vi78-84CrossRef
13.
Hiura Y, Takiguchi S, Yamamoto K, Kurokawa Y, Yamasaki M, Nakajima K, Miyata H, Fujiwara Y, Mori M, Doki Y (2012) Fall in plasma ghrelin concentrations after cisplatin-based chemotherapy in esophageal cancer patients. Int J Clin Oncol 17:316–323CrossRef
14.
Hiura Y, Takiguchi S, Yamamoto K, Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, Miyata H, Fujiwara Y, Mori M, Kangawa K, Doki Y (2012) Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: a prospective, randomized, placebo-controlled phase 2 study. Cancer 118:4785–4794CrossRef
15.
Okuyama T, Wang XS, Akechi T, Mendoza TR, Hosaka T, Cleeland CS, Uchitomi Y (2003) Japanese version of the MD Anderson symptom inventory: a validation study. J Pain Symptom Manag 26:1093–1104CrossRef
16.
Asakawa A, Inui A, Fujimiya M, Sakamaki R, Shinfuku N, Ueta Y, Meguid MM, Kasuga M (2005) Stomach regulates energy balance via acylated ghrelin and desacyl ghrelin. Gut 54:18–24CrossRef
17.
Takiguchi S, Adachi S, Yamamoto K, Morii E, Miyata H, Nakajima K, Yamasaki M, Kangawa K, Mori M, Doki Y (2012) Mapping analysis of ghrelin producing cells in the human stomach associated with chronic gastritis and early cancers. Dig Dis Sci 57:1238–1246CrossRef
18.
Taal BG, Boot H, van Heerde P, de Jong D, Hart AA, Burgers JM (1996) Primary non-Hodgkin lymphoma of the stomach: endoscopic pattern and prognosis in low versus high grade malignancy in relation to the MALT concept. Gut 39:556–561CrossRef
19.
Garcia JM, Li H, Mann D, Epner D, Hayes TG, Marcelli M, Cunningham GR (2006) Hypogonadism in male patients with cancer Cancer 106: 2583–2591CrossRef
20.
Malendowicz W, Ziolkowska A, Szyszka M, Kwias Z (2009) Elevated blood active ghrelin and unaltered total ghrelin and obestatin concentrations in prostate carcinoma. Urol Int 83:471–475CrossRef
21.
Markowska A, Ziółkowska A, Jaszczyńska-Nowinka K, Madry R, Malendowicz L (2009) Elevated blood plasma concentrations of active ghrelin and obestatin in benign ovarian neoplasms and ovarian cancers. Eur J Gynaecol Oncol 30:518–522PubMed
22.
Koyama KI, Yasuhara D, Nakahara T, Harada T, Uehara M, Ushikai M, Asakawa A, Inui A (2010) Changes in acyl ghrelin, des-acyl ghrelin, and ratio of acyl ghrelin to total ghrelin with short-term refeeding in female inpatients with restricting-type anorexia nervosa. Hormone and metabolic research = Hormon- und Stoffwechselforschung = hormones et metabolisme 42:595–598CrossRef
23.
Broglio F, Gianotti L, Destefanis S, Fassino S, Abbate Daga G, Mondelli V, Lanfranco F, Gottero C, Gauna C, Hofland L, Van der Lely AJ, Ghigo E (2004) The endocrine response to acute ghrelin administration is blunted in patients with anorexia nervosa, a ghrelin hypersecretory state. Clin Endocrinol 60:592–599CrossRef
24.
Miljic D, Pekic S, Djurovic M, Doknic M, Milic N, Casanueva FF, Ghatei M, Popovic V (2006) Ghrelin has partial or no effect on appetite, growth hormone, prolactin, and cortisol release in patients with anorexia nervosa. J Clin Endocrinol Metab 91:1491–1495CrossRef
25.
Temel JS, Abernethy AP, Currow DC, Friend J, Duus EM, Yan Y, Fearon KC (2016) Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol 17:519–531CrossRef
26.
Mitsunaga S, Kinoshita T, Hasebe T, Nakagohri T, Konishi M, Takahashi S, Gotohda N, Ochiai A (2008) Low serum level of cholinesterase at recurrence of pancreatic cancer is a poor prognostic factor and relates to systemic disorder and nerve plexus invasion. Pancreas 36:241–248CrossRef
27.
Han X, Wu Z, Di J, Pan Y, Zhang H, Du Y, Cheng Z, Jin Z, Wang Z, Zheng Q (2011) CXCL9 attenuated chemotherapy-induced intestinal mucositis by inhibiting proliferation and reducing apoptosis. Biomed Pharmacother 65:547–554CrossRef
28.
Soares PM, Lopes LO, Mota JMS, Belarmino-Filho JN, Ribeiro RA, de Souza MHL (2011) Methotrexate-induced intestinal mucositis delays gastric emptying and gastrointestinal transit of liquids in awake rats. Arquivos de gastroenterologia 48:80–85CrossRef
29.
Russo F, Linsalata M, Clemente C, D'Attoma B, Orlando A, Campanella G, Giotta F, Riezzo G (2013) The effects of fluorouracil, epirubicin, and cyclophosphamide (FEC60) on the intestinal barrier function and gut peptides in breast cancer patients: an observational study. BMC Cancer 13:56CrossRef
30.
Sibilia V, Rindi G, Pagani F, Rapetti D, Locatelli V, Torsello A, Campanini N, Deghenghi R, Netti C (2003) Ghrelin protects against ethanol-induced gastric ulcers in rats: studies on the mechanisms of action. Endocrinology 144:353–359CrossRef
31.
Warzecha Z, Ceranowicz D, Dembiński A, Ceranowicz P, Cieszkowski J, Kuwahara A, Kato I, Dembiński M, Konturek PC (2012) Ghrelin accelerates the healing of cysteamine-induced duodenal ulcers in rats Medical science monitor: international medical journal of experimental and clinical research 18: BR181
32.
Konturek P, Brzozowski T, Engel M, Burnat G, Gaca P, Konturek S (2009) Ghrelin ameliorates colonic inflammation. Role of nitric oxide and sensory nerves Acta physiologica Polonica 60: 41
33.
Waseem T, Duxbury M, Ito H, Rocha F, Lautz D, Whang E, Ashley S, Robinson M (2004) Ghrelin ameliorates TNF-a induced anti-proliferative and pro-apoptotic effects and promotes intestinal epithelial restitution Journal of the American College of Surgeons 199: 16CrossRef
34.
Nelson K, Walsh D, Sheehan F (2002) Cancer and chemotherapy-related upper gastrointestinal symptoms: the role of abnormal gastric motor function and its evaluation in cancer patients. Support Care Cancer : Off J Multinatl Assoc Support Care Cancer 10:455–461CrossRef
35.
Masuda Y, Tanaka T, Inomata N, Ohnuma N, Tanaka S, Itoh Z, Hosoda H, Kojima M, Kangawa K (2000) Ghrelin stimulates gastric acid secretion and motility in rats. Biochem Biophys Res Commun 276:905–908CrossRef
36.
Dornonville de la Cour C, Lindstrom E, Norlen P, Hakanson R (2004) Ghrelin stimulates gastric emptying but is without effect on acid secretion and gastric endocrine cells. Regul Pept 120:23–32CrossRef
37.
Edholm T, Levin F, Hellström PM, Schmidt PT (2004) Ghrelin stimulates motility in the small intestine of rats through intrinsic cholinergic neurons. Regul Pept 121:25–30CrossRef
Metadata
Title
Characterization of low active ghrelin ratio in patients with advanced pancreatic cancer
Authors
Tomofumi Miura
Shuichi Mitsunaga
Masafumi Ikeda
Izumi Ohno
Hideaki Takahashi
Hidetaka Suzuki
Ai Irisawa
Takeshi Kuwata
Atsushi Ochiai
Publication date
01-11-2018
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 11/2018
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-018-4248-4

Other articles of this Issue 11/2018

Supportive Care in Cancer 11/2018 Go to the issue

Original Article

A pragmatic comparative study of palliative care clinician’s reports of the degree of shadowing visible on plain abdominal radiographs

Original Article

Predictors of burden and quality of sleep among family caregivers of patients with cancer

Original Article

Mood, sexuality, and relational intimacy after starting androgen deprivation therapy: implications for couples

Original Article

Utility of Mayo Clinic’s early screen for discharge planning tool for predicting patient length of stay, discharge destination, and readmission risk in an inpatient oncology cohort

Original Article

Nasal vestibulitis: an under-recognized and under-treated side effect of cancer treatment?

Original Article

Impact of ferric carboxymaltose on the evolution of hemoglobin and ECOG performance status in iron-deficient patients with solid tumors: a 3-month follow-up retrospective study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits